SCHEMBL17200569

SCHEMBL17200569

O=C(O)CC1CCc2cc(-c3ccc(NC(=O)Nc4cccc([N+](=O)[O-])c4)cc3)ccc2C1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 2/20 0.76
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
POLB P06746 2/20 0.56
BAZ1A Q9NRL2 3/20 0.51
GAA P10253 1/20 0.51
CNR1 P21554 1/20 0.51
MAPT P10636 3/20 0.50
HTT P42858 2/20 0.50
DDX3X O00571 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
ITGB3 P05106 1/20 0.47
ITGA2B P08514 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14060436 0.87 DGAT1 (1.00) DGAT1MEN1KMT2ANPC1RAB9A
SCHEMBL17200609 0.85 DGAT1 (0.82) DGAT1NPC1RAB9ACNR1ITGB3
SCHEMBL17200593 0.85 DGAT1 (0.82) DGAT1MEN1KMT2ANPC1RAB9A
SCHEMBL17200553 0.85 DGAT1 (0.82) DGAT1NPC1RAB9ACNR1ITGB3
SCHEMBL17200540 0.82 DGAT1 (0.78) DGAT1MEN1KMT2ANPC1RAB9A
SCHEMBL17200585 0.82 DGAT1 (0.78) DGAT1MEN1KMT2ARAB9AMAPT
SCHEMBL17200615 0.82 DGAT1 (0.78) DGAT1MEN1KMT2AMAPTITGB3
SCHEMBL14059721 0.82 DGAT1 (0.78) DGAT1MEN1KMT2ARAB9AMAPT
SCHEMBL17200536 0.82 DGAT1 (0.78) DGAT1MEN1KMT2ANPC1RAB9A
SCHEMBL17200564 0.81 DGAT1 (0.83) DGAT1NPC1RAB9ACNR1ITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 EP claimed
EP-2723332-B1 NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-03-02 EP disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-9242929-B2 Compounds as diacylglycerol acyltransferase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-01-26 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) 2015-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307445-A1 Novel Compounds as Diacylglycerol Acyltransferase Inhibitors DGAT1, DGAT2, LCAT DGAT1 1/4885MEN1 4075/4885KMT2A 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.